Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Institute of Hematology, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
Wei-lai
WL
Xu
Jie
J
Jin
Wen-bin
WB
Qian
D015250:Aclarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006248:Harringtonines / Q000009:adverse effects / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome; D055815:Young Adult
D004338:Drug Combinations; D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D015250:Aclarubicin